Norepinephrine regulates locomotor hyperactivity in the mouse mutant coloboma

Pharmacology Biochemistry and Behavior

Volumn 75, Issue 1, 2003, Pages 209-216

  Jones, Michelle D ^a   Hess, Ellen J ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Attention deficit hyperactivity disorder; Coloboma; Dopamine; DSP 4; Hyperactivity; Mouse mutant; Norepinephrine; SNAP 25

Indexed keywords

2 BROMO N (2 CHLOROETHYL) N ETHYLBENZYLAMINE; DOPAMINE; NORADRENALIN; SEROTONIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLOBOMA; CONTROLLED STUDY; DOPAMINE RELEASE; HYPERACTIVITY; MALE; MOUSE; MOUSE MUTANT; NONHUMAN; NORADRENALIN BRAIN LEVEL; NORADRENALIN RELEASE; NORADRENERGIC SYSTEM; PRIORITY JOURNAL; SEROTONIN RELEASE;

ANIMALIA;

EID: 0037621425     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(03)00073-X     Document Type: Article

References (59)

1. Arnold L.E., Christopher J., Huestis R., Smeltzer D.J. Methylphenidate vs. dextroamphetamine vs. caffeine in minimal brain dysfunction. Arch. Gen. Psychiatry. 35:1978;463-473.
2. Barr C.L., Feng Y., Wigg K., Bloom S., Roberts W., Malone M.et al. Identification of DNA variants in the SNAP-25 gene and linkage study of these polymorphisms and attention-deficit hyperactivity disorder. Mol. Psychiatry. 5:2000;405-409.
3. Castellanos F.X., Elia J., Kruesi M.J., Gulotta C.S., Mefford I.N., Potter W.Z.et al. Cerebrospinal fluid monoamine metabolites in boys with attention-deficit hyperactivity disorder. Psychiatry Res. 52:1994;305-316.
4. Castellanos F.X., Elia J., Kruesi M.J., Marsh W.L., Gulotta C.S., Potter W.Z.et al. Cerebrospinal fluid homovanillic acid predicts behavioral response to stimulants in 45 boys with attention deficit/hyperactivity disorder. Neuropsychopharmacology. 14:1996;125-137.
5. Castellanos F.X., Lau E., Tayebi N., Lee P., Long R.E., Giedd J.N.et al. Lack of an association between a dopamine-4 receptor polymorphism and attention-deficit/hyperactivity disorder: genetic and brain morphometric analyses. Mol. Psychiatry. 3:1998;431-434.
6. 1A subunit of the P/Q-type calcium channel. EMBO J. 16:1997;4591-4596.
7. Colliver T.L., Hess E.J., Pothos E.N., Sulzer D., Ewing A.G. Quantitative and statistical analysis of the shape of amperometric spikes recorded from two populations of cells. J. Neurochem. 74:2000;1086-1097.
8. Comings D.E., Gade-Andavolu R., Gonzalez N., Blake H., Wu S., MacMurray J.P. Additive effect of three noradrenergic genes (ADRA2a, ADRA2C, DBH) on attention-deficit hyperactivity disorder and learning disabilities in Tourette syndrome subjects. Clin. Genet. 55:1999;160-172.
9. Comings D.E., Gade-Andavolu R., Gonzalez N., Wu S., Muhleman D., Blake H.et al. Multivariate analysis of associations of 42 genes in ADHD, ODD and conduct disorder. Clin. Genet. 58:2000;31-40.
10. Cook E.H., Stein M.A., Krasowski M.D., Cox N.J., Olkon D.M., Kieffer J.E.et al. Association of attention-deficit disorder and the dopamine transporter gene. Am. J. Hum. Genet. 56:1995;993-998.
11. Elia J., Borcherding B.G., Rapoport J.L., Keysor C.S. Methylphenidate and dextroamphetamine treatments of hyperactivity: Are there true nonresponders? Psychiatry Res. 36:1991;141-155.
12. Faraone S.V., Biederman J., Weiffenbach B., Keith T., Chu M.P., Weaver A.et al. Dopamine D4 gene 7-repeat allele and attention deficit hyperactivity disorder. Am. J. Psychiatry. 156:1999;768-770.
13. Feng J., Sobell J.L., Heston L.L., Goldman D., Cook E., Kranzler H.R.et al. Variants in the alpha2A AR adrenergic receptor gene in psychiatric patients. Am. J. Med. Genet. 81:1998;405-410.
14. Fritschy J.M., Grzanna R. Restoration of ascending noradrenergic projections by residual locus coeruleus neurons: compensatory response to neurotoxin-induced cell death in the adult rat brain. J. Comp. Neurol. 321:1992;421-441.
15. Gill M., Daly G., Heron S., Hawi Z., Fitzgerald M. Confirmation of association between attention deficit hyperactivity disorder and a dopamine transporter polymorphism. Mol. Psychiatry. 2:1997;311-313.
16. Harkin A., Morris K., Kelly J.P., O'Donnell J.M., Leonard B.E. Modulation of MK-801-induced behaviour by noradrenergic agents in mice. Psychopharmacology (Berl.). 154:2001;177-188.
17. Harro J., Merikula A., Lepiku M., Modiri A.R., Rinken A., Oreland L. Lesioning of locus coeruleus projections by DSP-4 neurotoxin treatment: effect on amphetamine-induced hyperlocomotion and dopamine D2 receptor binding in rats. Pharmacol. Toxicol. 86:2000;197-202.
18. Hess E.J., Jinnah H.A., Kozak C.A., Wilson M.C. Spontaneous locomotor hyperactivity in a mouse mutant with a deletion including the Snap gene on chromosome 2. J. Neurosci. 12:1992;2865-2874.
19. Hess E.J., Collins K.A., Copeland N.G., Jenkins N.A., Wilson M.C. Deletion map of the coloboma (Cm) locus on mouse chromosome 2. Genomics. 21:1994;257-261.
20. Hess E.J., Collins K.A., Wilson M.C. Mouse model of hyperkinesis implicates SNAP-25 in behavioral regulation. J. Neurosci. 16:1996;3104-3111.
21. Hunt R.D., Minderaa R.B., Cohen D.J. Clonidine benefits children with attention deficit disorder and hyperactivity: report of a double-blind placebo-crossover therapeutic trial. J. Am. Acad. Child Psychiatry. 24:1985;617-629.
22. Hunt R.D., Arnsten A.F., Asbell M.D. An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry. 34:1995;50-54.
23. Jones M.D., Williams M.E., Hess E.J. Abnormal presynaptic catecholamine regulation in a hyperactive SNAP-25-deficient mouse mutant. Pharmacol. Biochem. Behav. 68:2001;669-676.
24. Jones M.D., Williams M.E., Hess E.J. Expression of catecholaminergic mRNAs in the hyperactive mouse mutant coloboma. Brain Res. Mol. Brain Res. 96:2001;114-121.
25. Jonsson G., Hallman H., Ponzio F., Ross S. DSP4 (N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine) - a useful denervation tool for central and peripheral noradrenaline neurons. Eur. J. Pharmacol. 72:1981;173-188.
26. Khan A.U., Dekirmenjian H. Urinary excretion of catecholamine metabolites in hyperkinetic child syndrome. Am. J. Psychiatry. 138:1981;108-110.
27. 2+ channels with presynaptic SNARE proteins. Proc. Natl. Acad. Sci. 94:1997;14782-14786.
28. LaHoste G.J., Swanson J.M., Wigal S.B., Glabe C., Wigal T., King N.et al. Dopamine D4 receptor gene polymorphism is associated with attention deficit hyperactivity disorder. Mol. Psychiatry. 1:1996;121-124.
29. Lapiz M.D., Mateo Y., Parker T., Marsden C. Effects of noradrenaline depletion in the brain on response on novelty in isolation-reared rats. Psychopharmacology (Berl.). 152:2000;312-320.
30. Linial M., Ilouz N., Parnas H. Voltage-dependent interaction between the muscarinic ACh receptor and proteins of the exocytic machinery. J. Physiol. 504:1997;251-258.
31. Lou H.C., Henriksen L., Bruhn P., Borner H., Nielsen J.B. Striatal dysfunction in attention deficit and hyperkinetic disorder. Arch. Neurol. 46:1989;48-52.
32. Lou H.C., Henriksen L., Bruhn P. Focal cerebral dysfunction in developmental learning disabilities. Lancet. 335:1990;8-11.
33. Malone M.A., Swanson J.M. Effects of methylphenidate on impulsive responding in children with attention-deficit hyperactivity disorder. J. Child Neurol. 8:1993;157-163.
34. Malone M.A., Kershner J.R., Swanson J.M. Hemispheric processing and methylphenidate effects in attention-deficit hyperactivity disorder. J. Child Neurol. 9:1993;181-189.
35. McCracken J.T. A two-part model of stimulant action on attention-deficit hyperactivity disorder in children. J. Neuropsychiatry Clin. Neurosci. 3:1991;201-209.
36. Mefford I.N., Potter W.Z. A neuroanatomical and biochemical basis of attention deficit disorder with hyperactivity in children: a defect in tonic adrenaline mediated inhibition of locus ceruleus stimulation. Med. Hypotheses. 29:1989;33-42.
37. Mill J., Curran S., Kent L., Gould A., Huchkett L., Richards S.et al. Association study of a SNAP-25 microsatellite and attention deficit hyperactivity disorder. Am. J. Med. Genet. 114:2002;269-271.
38. Ogren S.O., Archer T., Johansson C. Evidence for a selective brain noradrenergic involvement in the locomotor stimulant effects of amphetamine in the rat. Neurosci. Lett. 43:1983;327-331.
39. Pliszka S.R., McCracken J.T., Maas J.W. Catecholamines in attention-deficit hyperactivity disorder: current perspectives. J. Am. Acad. Child Adolesc. Psychiatry. 35:1996;264-272.
40. Raber J., Mehta P.P., Kreifeldt M., Parsons L.H., Weiss F., Bloom F.E.et al. Coloboma hyperactive mutant mice exhibit regional and transmitter-specific deficits in neurotransmission. J. Neurochem. 68:1997;176-186.
41. Rapoport J.L., Mikkelsen E.J., Ebert M.H., Brown G.L., Weise V.K., Kopin I.J. Urinary catecholamines and amphetamine excretion in hyperactive and normal boys. J. Nerv. Ment. Dis. 166:1978;731-737.
42. 2+ channels with the presynaptic proteins syntaxin and SNAP-25. Proc. Natl. Acad. Sci. 93:1996;7363-7368.
43. Rowe D.C., Stever C., Giedinghagen L.N., Gard J.M., Cleveland H.H., Terris S.T.et al. Dopamine DRD4 receptor polymorphism and attention deficit hyperactivity disorder. Mol. Psychiatry. 3:1998;419-426.
44. Russell V., Allie S., Wiggins T. Increased noradrenergic activity in prefrontal cortex slices of an animal model for attention-deficit hyperactivity disorder - the spontaneously hypertensive rat. Behav. Brain Res. 117:2000;69-74.
45. Shekim W.O., Dekirmenjian H., Chapel J.L. Urinary MHPG excretion in minimal brain dysfunction and its modification by d-amphetamine. Am. J. Psychiatry. 136:1979;667-671.
46. Shekim W.O., Javaid J., Davis J.M., Bylund D.B. Urinary MHPG and HVA excretion in boys with attention deficit disorder and hyperactivity treated with d-amphetamine. Biol. Psychiatry. 18:1983;707-714.
47. Shenker A. The mechanism of action of drugs used to treat attention-deficit hyperactivity disorder: focus on catecholamine receptor pharmacology. Adv. Pediatr. 39:1992;337-382.
48. Smalley S.L., Bailey J.N., Palmer C.G., Cantwell D.P., McGough J.J., Del'Homme M.A.et al. Evidence that the dopamine D4 receptor is a susceptibility gene in attention deficit hyperactivity disorder. Mol. Psychiatry. 3:1998;427-430.
49. Snyder D.L., Aloyo V.J., McIlvain H.B., Johnson M.D., Roberts J. Effect of age on potassium- and tyramine-induced release of norepinephrine from cardiac synaptosomes in male F344 rats. J. Gerontol. 47:1992;B190-B197.
50. Söllner T., Bennett T., Whiteheart S.W., Scheller R.H., Rothman J.E. A protein assembly-disassembly pathway in vitro that may correspond to sequential steps of synaptic vesicle docking, activation and fusion. Cell. 75:1993;409-418.
51. Stanley E.F., Mirotznik R.R. Cleavage of syntaxin prevents G-protein regulation of presynaptic calcium channels. Nature. 385:1997;340-343.
52. Theiler K., Varnum D.S. Development of coloboma (Cm/+), a mutation with anterior lens adhesion. Anat. Embryol. 161:1981;121-126.
53. Todd R.D., Sitdhiraksa N., Reich W., Ji T.H., Joyner C.A., Heath A.C.et al. Discrimination of DSM-IV and latent class attention-deficit/hyperactivity disorder subtypes by educational and cognitive performance in a population-based sample of child and adolescent twins. J. Am. Acad. Child Adolesc. Psychiatry. 41:2002;820-828.
54. Waldman I.D., Rowe D.C., Abramowitz A., Kozel S.T., Mohr J.H., Sherman S.L.et al. Association and linkage of the dopamine transporter gene and attention-deficit hyperactivity disorder in children: heterogeneity owing to diagnostic subtype and severity. Am. J. Hum. Genet. 63:1998;1767-1776.
55. Washbourne P., Thompson P.M., Carta M., Costa E.T., Mathews J.R., Lopez-Bendito G.et al. Genetic ablation of the t-SNARE SNAP-25 distinguishes mechanisms of neuroexocytosis. Nat. Neurosci. 5:2002;19-26.
56. Weber T., Zemelman B.V., McNew J.A., Westermann B., Gmachl M., Parlati F.et al. SNAREpins: minimal machinery for membrane fusion. Cell. 92:1998;759-772.
57. 2+ channels. EMBO J. 15:1996;4100-4110.
58. Xue Y., Gao X., Lindsell C.E., Norton C.R., Chang B., Hicks C.et al. Embryonic lethality and vascular defects in mice lacking the Notch ligand Jagged1. Hum. Mol. Genet. 8:1999;723-730.
59. Zametkin A.J., Karoum F., Linnoila M., Rapoport J.L., Brown G.L., Chuang L.W.et al. Stimulants, urinary catecholamines, and indoleamines in hyperactivity. A comparison of methylphenidate and dextroamphetamine. Arch. Gen. Psychiatry. 42:1985;251-255.